Cassava Sciences, Inc. (NASDAQ:FLNA – Get Free Report) CEO Richard Barry bought 93,091 shares of the business’s stock in a transaction that occurred on Monday, September 28th. The stock was acquired at an average cost of $0.84 per share, with a total value of $78,196.44. Following the completion of the acquisition, the chief executive officer owned 1,031,151 shares of the company’s stock, valued at $866,166.84. This represents a 9.92% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Cassava Sciences Stock Down 4.2%
Cassava Sciences stock traded down $0.04 during mid-day trading on Wednesday, reaching $0.89. 761,805 shares of the company’s stock traded hands, compared to its average volume of 1,019,458. The company has a market cap of $42.80 million, a price-to-earnings ratio of -1.02 and a beta of -0.69. The stock has a 50 day moving average of $0.88 and a two-hundred day moving average of $1.27. Cassava Sciences, Inc. has a 12-month low of $0.67 and a 12-month high of $4.98.
Cassava Sciences (NASDAQ:FLNA – Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.18) EPS for the quarter.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Analysis on Cassava Sciences
Institutional Investors Weigh In On Cassava Sciences
An institutional investor recently raised its position in Cassava Sciences stock. Caitong International Asset Management Co. Ltd lifted its position in Cassava Sciences, Inc. (NASDAQ:FLNA – Free Report) by 465.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,606 shares of the company’s stock after acquiring an additional 11,200 shares during the quarter. Caitong International Asset Management Co. Ltd’s holdings in Cassava Sciences were worth $27,000 at the end of the most recent reporting period. Institutional investors own 38.05% of the company’s stock.
About Cassava Sciences
Cassava Sciences, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company’s research has centered on simufilam, an investigational oral therapy designed to target an altered form of the scaffolding protein filamin A that Cassava has linked to Alzheimer’s disease pathology.
Simufilam has been evaluated in clinical studies involving patients with Alzheimer’s disease, but it is an investigational product and is not approved for commercial use.
Read More
- Five stocks we like better than Cassava Sciences
- Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
- O’Reilly Automotive’s Stock Slump Hides a Stronger Business
- McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
- Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
